16 min listen
Finding New Uses for TNF Inhibitors
FromThe Bio Report
ratings:
Length:
22 minutes
Released:
Apr 8, 2021
Format:
Podcast episode
Description
TNF inhibitors, such as Humira and Remicade, have been a great biotech success story. These multi-billion franchises treat a range of autoimmune conditions including rheumatoid arthritis, psoriasis, and Crohn’s disease. Jim Woody, who led Centocor’s development team for Remicade, the first of the TNF-inhibitors, is today in pursuit of new uses for these therapies. Now CEO of 180 Life Sciences, Woody and his team are pushing TNF inhibitors into new indications for inflammatory and fibrotic conditions. We spoke to Woody about the role of TNF in the inflammatory process, the indications his company is pursuing, and why these well-established drugs have gone untapped for these purposes. The Bio Report welcomes DeepDyve as a sponsor. Search 100 million scientific papers with full access to 20 million articles. It’s one-stop, affordable research. Try the enterprise version of the service free for one month. Go to deepdyve.com/podcast and use the code BIOREPORT
Released:
Apr 8, 2021
Format:
Podcast episode
Titles in the series (100)
Promise Shown in Different Approach to Alzheimer’s: AgeneBio is developing drugs to treat the pre-dementia stage of Alzheimer’s disease, and other neurological and psychiatric conditions. The company announced encouraging mid-stage results for its lead therapeutic, which works by quieting hyperactivit... by The Bio Report